Henry J Kaminski Selected Research

Cholinergic Receptors

1/2022	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study.
12/2020	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.
11/2020	Minimal manifestation status and prednisone withdrawal in the MGTX trial.
10/2020	The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model.
1/2020	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America.
1/2020	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
1/2019	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
1/2018	Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement.
11/2016	Randomized Trial of Thymectomy in Myasthenia Gravis.
4/2015	A genome-wide association study of myasthenia gravis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Henry J Kaminski Research Topics

Disease

54	Myasthenia Gravis 01/2022 - 03/2002
8	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 01/2017 - 11/2002
6	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 09/2003
5	Thymoma (Thymic Carcinoma) 11/2020 - 09/2003
5	Inflammation (Inflammations) 01/2018 - 03/2003
4	Muscle Weakness 10/2021 - 12/2006
3	Rare Diseases (Rare Disease) 10/2021 - 10/2012
3	Neuromuscular Junction Diseases 02/2008 - 11/2002
3	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2008 - 02/2002
3	Fibrosis (Cirrhosis) 01/2008 - 02/2002
1	Hyperplasia 12/2020
1	Infections 05/2019
1	Long Term Adverse Effects 11/2018
1	Fatigue 01/2018
1	Camptocormia 06/2017
1	Frailty 03/2016
1	Thymus Hyperplasia 02/2016
1	Disease Progression 02/2016
1	Myotonia 10/2012
1	Respiratory Insufficiency (Respiratory Failure) 12/2010
1	Nervous System Diseases (Neurological Disorders) 01/2008
1	Stroke (Strokes) 01/2008
1	Walker-Warburg Syndrome 03/2006
1	Muscular Dystrophies (Muscular Dystrophy) 03/2003
1	Necrosis 02/2002

Drug/Important Bio-Agent (IBA)

19	Cholinergic ReceptorsIBA 01/2022 - 11/2002
10	AutoantibodiesIBA 01/2022 - 11/2002
10	Complement System Proteins (Complement)IBA 06/2019 - 10/2004
9	Prednisone (Sone)FDA LinkGeneric 01/2022 - 01/2008
7	Proteins (Proteins, Gene)FDA Link 12/2020 - 03/2006
5	margatoxinIBA 11/2020 - 01/2008
5	AntibodiesIBA 05/2019 - 01/2008
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2014
3	Pharmaceutical PreparationsIBA 01/2020 - 08/2015
3	Complement Inactivating AgentsIBA 01/2020 - 01/2009
3	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2019 - 06/2007
3	Phosphotransferases (Kinase)IBA 10/2017 - 02/2011
3	Biomarkers (Surrogate Marker)IBA 01/2017 - 01/2008
3	DystrophinIBA 01/2008 - 02/2002
2	GlucocorticoidsIBA 01/2022 - 01/2017
2	SurvivinIBA 10/2020 - 01/2014
2	Messenger RNA (mRNA)IBA 01/2018 - 01/2006
2	Interleukin-17 (Interleukin 17)IBA 01/2017 - 02/2016
2	RNA (Ribonucleic Acid)IBA 01/2016 - 06/2014
2	CD55 Antigens (Decay Accelerating Factor)IBA 12/2006 - 11/2002
1	Matrix Metalloproteinases (MMPs)IBA 10/2021
1	Monoclonal AntibodiesIBA 10/2020
1	Peptides (Polypeptides)IBA 10/2020
1	zilucoplanIBA 01/2020
1	glucose-mannose-glucoseIBA 01/2020
1	Small Interfering RNA (siRNA)IBA 06/2019
1	AcetylgalactosamineIBA 06/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2019
1	Edrophonium (Tensilon)FDA LinkGeneric 01/2019
1	pembrolizumabIBA 10/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	polyetheretherketoneIBA 01/2018
1	OsteopontinIBA 01/2017
1	CytokinesIBA 01/2017
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 05/2015
1	DNA (Deoxyribonucleic Acid)IBA 04/2015
1	Immunomodulating AgentsIBA 04/2015
1	Mexiletine (Mexitil)FDA LinkGeneric 10/2012
1	Intravenous Immunoglobulins (IVIG)FDA Link 12/2010
1	AutoantigensIBA 02/2008
1	Protein Kinases (Protein Kinase)IBA 02/2008
1	UtrophinIBA 01/2008
1	protein O-mannose beta-1,2-N-acetylglucosaminyltransferaseIBA 03/2006
1	Mannose (D-Mannose)IBA 03/2006
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2006
1	Transforming Growth Factor beta3 (TGF beta 3)IBA 01/2006
1	Transforming Growth Factor beta2IBA 01/2006
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 01/2006
1	ChemokinesIBA 03/2003
1	CollagenIBA 02/2002

Therapy/Procedure

16	Thymectomy 12/2020 - 03/2002
13	Therapeutics 11/2020 - 09/2003
2	Plasma Exchange 05/2011 - 04/2011
1	Activities of Daily Living (ADL) 01/2020
1	RNAi Therapeutics 06/2019
1	Intraperitoneal Injections 06/2014
1	Plasmapheresis 04/2011
1	Length of Stay 12/2010
1	Immunotherapy 03/2003